Abstract: A thermistor has a mixture of a temperature sensitive material and a conductive material, and an electrode in electrical contact with the mixture. A method of manufacturing a thermistor includes depositing conductive contacts onto a substrate, printing a thermistor mixture of temperature sensitive material and a conductive material over the contact, and annealing the thermistor mixture to produce a flexible thermistor on the conductive contacts.

Abstract: A method of fabricating a drug-transfer device includes forming a package having a first component retaining multiple volumes of a drug and a second component retaining an agent. The first component and the second component are integrally formed together. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The method allows exterior surfaces of the first and second components to be cleanable (e.g., prior to final assembly). After such cleaning, either no or substantially no amount of drug and agent is present outside the package. According to some embodiments, the package may be fabricated such that either no or substantially no amount of the drug is present within the second component and such that either no or substantially no amount of the agent is present within the first component.

Abstract: A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.

Abstract: A fluid flow control and debris intercepting apparatus for controlling the flow of fluid and the introduction of debris into the entrance of a water diversion system such as a curbside storm drain.

Abstract: This invention relates to 2-aza-bicyclo[2.2.1]heptane compounds (and salts thereof), the process for making such a compound and pharmaceutical compositions comprising such a compound. The invention also relates to the use of the compounds for modulating the glycine transporter 1 (GlyT1) and for the treatment of psychosis, cognitive disorders, bipolar disorders, depression disorders, anxiety disorders, post-traumatic stress disorders and pain.

Abstract: A composition is provided that includes a ternary electrolyte having a melting point greater than about 150 degree Celsius. The ternary electrolyte includes an alkali metal halide, an aluminum halide and a zinc halide. The amount of the zinc halide present in the ternary electrolyte is greater than about 20 mole percent relative to an amount of the aluminum halide. An energy storage device including the composition is provided. A system and a method are also provided.

Abstract: A method of enabling administration of a drug includes determining, within a drug-transfer device including cells, a location of at least one cell and generating information identifying the determined location. A user may be provided with the drug-transfer device. The drug is retained within the at least one cell when the user is provided with the drug-transfer device. The method also includes encoding a key with the information and providing the user with the key before, after or when the user is provided with the drug-transfer device. Drug retained within the at least one cell is selectively releasable when the key is operably proximate to the drug-transfer device and is encoded with the information. The key can be encoded with the information before and/or after being provided to the user. In some embodiments, the key is encoded based on instructions transmitted over a network.

Abstract: Devices capable of deterring or preventing bulk extraction of drugs from, for example, drug-delivery systems are exemplarily disclosed. In one embodiment, such a device may include a package releasably retaining a drug and an agent. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The cell package is configured such that an amount of the drug is selectively releasable with respect to the agent when the package is operably proximate to an encoded key. The package, however, may be configured to impose a relatively high likelihood that either the drug will not be accessed or the drug will be contaminated by the agent if access to the contents of the package is sought without the use of an encoded key.

Abstract: A method of fabricating a drug-transfer device includes forming a package having a first component retaining multiple volumes of a drug and a second component retaining an agent. The first component and the second component are integrally formed together. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The method allows exterior surfaces of the first and second components to be cleanable (e.g., prior to final assembly). After such cleaning, either no or substantially no amount of drug and agent is present outside the package. According to some embodiments, the package may be fabricated such that either no or substantially no amount of the drug is present within the second component and such that either no or substantially no amount of the agent is present within the first component.

Abstract: An atom probe includes a specimen mount that can hold a specimen to be analyzed. A detector is spaced apart from the specimen mount. Between the detector and specimen mount Is a local electrode with an aperture. A laser is oriented to emit a laser beam toward the specimen mount at a nonzero angle with respect to the aperture plane, the aperture plane being oriented perpendicular to an ion travel path defined through the aperture between the specimen mount and detector.

Abstract: A drug deactivation system according to some embodiments includes at least one degradable capsule exposed to at least one drug-retaining region of a drug delivery device and an agent. The agent is configured to render a drug ineffective upon degradation of the at least one capsule. The at least one drug-retaining region is configured to retain one of the drug and the agent and the at least one capsule is configured to retain the other of the drug and the agent.

Abstract: Compounds represented by Formula (I): are useful in treating diseases, such as cancer, that are mediated and/or associated (at least in part) with DNMT3b activity. The compounds can be formulated as pharmaceutically acceptable compositions for administration to a subject in need thereof.

Abstract: A drug deactivation system according to some embodiments includes at least one degradable capsule exposed to at least one drug-retaining region of a drug delivery device and an agent. The agent is configured to render a drug ineffective upon degradation of the at least one capsule. The at least one drug-retaining region is configured to retain one of the drug and the agent and the at least one capsule is configured to retain the other of the drug and the agent.

Abstract: A system for use with a drug delivery device includes a sensor unit and a deactivation unit operatively coupled to an output of the sensor unit and to a drug-retaining region of the drug delivery device, wherein the drug-retaining region contains a drug. The sensor unit is configured to detect a characteristic of a local environment and generate an output corresponding to a value of the detected characteristic. The deactivation unit is configured to render the drug ineffective when the output of the sensor unit satisfies a predetermined condition.

Abstract: A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.

Abstract: A rotary method for forming a vaginal applicator. The method includes the steps of providing a forming mandrel, an applicator tube, and die then arranging the forming mandrel to be inside the applicator tube and then engaging the forming mandrel and the applicator tube with the die. The forming mandrel has a first sustaining ridge having a circumferential length and a second sustaining ridge having a circumferential length. The circumferential length of the first sustaining ridge is less than the circumferential length of the second sustaining ridge.

Abstract: A rotary method for forming a vaginal applicator. The method includes the steps of providing a forming mandrel, an applicator tube, and die then arranging the forming mandrel to be inside the applicator tube and then engaging the forming mandrel and the applicator tube with the die. The forming mandrel has a first sustaining ridge having a circumferential length and a second sustaining ridge having a circumferential length. The circumferential length of the first sustaining ridge is less than the circumferential length of the second sustaining ridge.

Abstract: An actuator assembly for hand-grippable devices, such as levers for a brake or clutch, triggers, scissor-action tools, etc. The actuator assembly is a lever having a rotation-restriction mechanism, such as a one-way bearing, mounted on a shaft, with a sleeve assembled over the rotation-restriction mechanism and shaft. As the lever is grasped by the fingertips and pulled toward the operator's palm, the sleeve rotates about the shaft axis, thereby allowing the lever to roll from the fingertips toward the base of the fingers near palm of the operator's hand, where the operator has greater strength and control over the lever. The sleeve is prevented from rotating in the reverse direction, so, when the operator releases the lever, the lever slides along toward the fingertips, allowing the operator to slow the motion as desired. The actuator assembly reduces fatigue and loss of control over hand-operated mechanisms.

Abstract: This invention relates to novel compounds having the structural formula Ia or formula Ib: Ia Ib and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of A? related pathologies such as cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

Abstract: A composition is provided that includes a ternary electrolyte having a melting point greater than about 150 degree Celsius. The ternary electrolyte includes an alkali metal halide, an aluminum halide and a zinc halide. The amount of the zinc halide present in the ternary electrolyte is greater than about 20 mole percent relative to an amount of the aluminum halide. An energy storage device including the composition is provided. A system and a method are also provided.